Sildenafil Citrate Tablet
Product Images NDC 72603-883

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72603-883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil Citrate Tablets 100 mg (NDC 72603-885-02)

This is a description of Sildenafil tablets, each containing 100 mg of Sildenafil citrate. The tablets are dispensed in child-resistant packaging and stored at room temperature. The product is manufactured in India by Umedica Laboratories Pvt. Ltd. and distributed by Northstar Rx LLC in Memphis, TN. For dosage information and prescribing details, refer to the accompanying information.*

FDA Label Image

Sildenafil Citrate Tablets 100 mg (NDC 72603-885-01)

This is information about Sildenafil, which is a medication used to treat erectile dysfunction. Each tablet contains 100 mg of Sildenafil citrate and the package contains 30 tablets. It is recommended to store the tablets at around 25°C (77°F). The medication is manufactured in India by Umedica Laboratories Pvt. Ltd. for Northstar Rx LLC in Memphis, TN. Dosage and usage information can be found in the accompanying prescribing information.*

FDA Label Image

Sildenafil Citrate Tablets 25 mg (NDC 72603-883-01)

This is a pharmaceutical product information for Sildenafil tablets containing 25 mg of Sildenafil citrate, manufactured in India. The package contains 30 tablets and should be stored at 25°C (77°F). It includes dosage and usage instructions. The tablets are dispensed in tight containers and come in child-resistant packaging. The product is manufactured by Untica Laboratories Pvt Ltd for Northstar R LLC.*

FDA Label Image

Sildenafil Citrate Tablets 50 mg (NDC 72603-884-01)

This is a description of a medication in tablet form containing Sildenafil citrate, with each tablet containing 0.50 mg of the active ingredient. The tablets are manufactured by Umedica Laboratories Pvt. Ltd. in Vapi, Gujarat, India. The packaging is child-resistant and should be stored in tight containers at controlled room temperature. The dosage and usage instructions are provided in the accompanying prescribing information. The National Drug Code (NDC) for this medication is 72603-884-01. This product comes in a package containing 30 tablets and the batch number is NoRTHS'rAgz Iss. 01/26, V-00 206298.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

This text provides information about the change in Systolic Blood Pressure (SBP) in mmHG at various post-dose time intervals. It compares the SBP changes between a combination of Doxazosin and Placebo and a combination of Doxazosin and Sildenafil 25 mg. This data can be used to analyze the effects of these medications on blood pressure.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

This data appears to show a comparison of the change in S8 blood pressure (measured in mmHG) between a group treated with Doxazosin and Placebo, and another group treated with Doxazosin and Sildenafil 50 mg. The graph displays the values over different time intervals postdose.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

This text presents information on the effect of sildenafil citrate and a placebo on the maintenance of erection based on baseline scores of patients. It indicates that 9% of patients reached the endpoint. The data seems to be related to a study or clinical trial evaluating the efficacy of these treatments in relation to baseline scores.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

This data represents the percentage of patients reporting improvement after taking different doses of Sildenafil citrate compared to placebo. The results show that the treatment groups with different doses of Sildenafil citrate (25mg, 50mg, and 100mg) had higher percentages of patients reporting improvement compared to the placebo group. The overall treatment effect was statistically significant (p<0.0001), with the highest improvement percentage observed in the group that received 100mg of Sildenafil citrate.*

FDA Label Image

Sildenafil-citrate-structure (Sildenafil Citrate Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.